Erodible intrauterine device

• US 3,888,975 A
• Filed: 12/27/1972
• Issued: 06/10/1975
• Est. Priority Date: 12/27/1972
• Status: Expired due to Term

• Current Assignee: Peter W. Ramwell
• Original Assignee: Peter W. Ramwell
• Inventors: Ramwell, Peter W.
• Primary Examiner(s): Rose, Shep K.
• Application Number:
  US05/318,890
• Time in Patent Office: 895 Days
• Field of Search: 424/15-22 128/260,130
• US Class Current: 424/432
• CPC Class Codes: A61F 6/144 with T-configuration
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 9/0039 Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
• CPC Class Codes: A61K 9/2063 Proteins, e.g. gelatin

Abstract

An intrauterine device for administering drug locally to the uterus at a controlled rate for a prolonged period of time is disclosed. The device contains a body of polymer capable of bioeroding in the environment of the uterus over a prolonged period of time. This body has the drug dispersed throughout so that as the body gradually bioerodes, it slowly releases the dispersed drug. In a preferred embodiment, the device releases a uterine contraction-inducing prostaglandin locally to the uterus at a controlled rate over a prolonged period of time.

Claims

1. AN INTRAUTERINE DEVICE FOR THE CONTROLLED LOCAL ADMINISTRATION OF PROSTAGLANDIN TO THE UTERUS COMPRISING A HOLLOW CERVICAL CYLINDRICAL BODY HAVING A CENTRAL PASSEGWAY SHAPED AND SIZED FOR INSERTION AND RETENTION IN THE UTERUS, THE BODY MADE OF A RELEASE RATE CONTROLLING MATERIAL CONSISTING ESSENTIALLY OF CROSS-LINKED GELATIN THAT IS CROSS-LINKED WITH A MEMBER SELECTED FROM THE GROUP CONSISTING OF AN ALDEHYDE, KETONE, CARBONDIMIDE AND DICARBOXYLIC ACID AT A CONCENTRATION OF 0.01 TO 60% BY WEIGHT OF GELATIN AT A TEMPERATURE OF 4*C TO 35*C FOR A REACTION PERIOD OF 0.1 HOUR TO 5 DAYS, THE MATERIAL CONTAINING FROM ABOUT 250 MICROGRAMS TO ABOUT 100 MILLIGRAMS OF A PROSTAGLANDIN THAT INDUCES UTERINE CONTRACTIONS, THE RELEASE RATE CONTROLLING MATERIAL BIOERODING AT A CONTROLLED RATE OVER A PERIOD OF 3 HOURS TO 30 DAYS IN RESONSE TO THE ENVIRONMENT OF THE UTERUS AND CONCURRENTLY THEREWITH RELEASING 1 MICROGRAM TO 25 MICROGRAMS PER HOUR OF THE DISPERSED PROSTAGLANDIN TO THE UTERUS TO PRODUCE THE DESIRED RESULT.

2. The device in accordance with claim 1 wherein the prostaglandin is selected from the group consisting of 11 Alpha , 15(S)-dihydroxy-9-oxo-13-trans-prostenoic acid;

11 Alpha ,15(S)-dihydroxy-9-oxo-5-cis-13trans-prostadienoic acid;

9 Alpha ,11 Alpha ,15(S)-trihydroxy-5-cis-13-trans-prostatrienoic acid; and

methyl 9 Alpha ,11 Alpha ,15(S)-trihydroxy-5-cis-13-trans-prostatrienoate.